Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial intelligence (AI), announced its financial results for the first quarter ended March 31, 2025 (“Q1 2025”), and provided an update on recent corporate developments. Q1 2025 Financial High ...